NIH VideoCast - Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs

Loading... Loading video...

299 Views

Air date:	Wednesday, January 25, 2017, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 299 (110 Live, 189 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:06:01
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director’s Wednesday Afternoon Lecture Series There's a growing interest in how the derivation of many different cell types from human pluripotent stem cells-embryonic stem cells (HESCs) and induced pluripotent stem cells (hiPS cells)-could be used for potential cell therapy and as a platform for drug discovery and toxicity. In particular, new methods of introducing specific disease mutations into human pluripotent stem cells and/or reprogramming them to derive hiPS cells, allow the creation of disease models "in a dish" so scientists can study ways to treat diseases or slow them down. To move the field forward, it's essential that scientists understand the underlying developmental mechanisms that control differentiation of pluripotent cells to their derivatives and mimic these in conditions in vitro. The Mummery lab has used these methods to produce isogenic pairs of hiPSC lines to compare diseased and corresponding control cardiomyocytes and vascular endothelial cells and identify disease-related phenotypes and mechanisms. The lab has also examined how hESC-derived cardiomyocytes respond to a variety of cardiac and non-cardiac drugs and has shown that iPSC-derived cardiomyocytes with mutations in ion-channel genes can accurately predict changes in cardiac electrical properties and reveal drug sensitivities. Dr. Mummery will describe similar studies that use vascular endothelial cells from hPSC and discuss the appropriate bioassays to measure disease phenotypes. For more information go to https://oir.nih.gov/wals

NLM Title:	Human pluripotent stem cells in understanding genetic cardiovascular disease and effects of drugs / Christine Mummery.
Author:	Mummery, C L. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director's Wednesday Afternoon Lecture Series. There's a growing interest in how the derivation of many different cell types from human pluripotent stem cells-embryonic stem cells (HESCs) and induced pluripotent stem cells (hiPS cells)-could be used for potential cell therapy and as a platform for drug discovery and toxicity. In particular, new methods of introducing specific disease mutations into human pluripotent stem cells and/or reprogramming them to derive hiPS cells, allow the creation of disease models "in a dish" so scientists can study ways to treat diseases or slow them down. To move the field forward, it's essential that scientists understand the underlying developmental mechanisms that control differentiation of pluripotent cells to their derivatives and mimic these in conditions in vitro. The Mummery lab has used these methods to produce isogenic pairs of hiPSC lines to compare diseased and corresponding control cardiomyocytes and vascular endothelial cells and identify disease-related phenotypes and mechanisms. The lab has also examined how hESC-derived cardiomyocytes respond to a variety of cardiac and non-cardiac drugs and has shown that iPSC-derived cardiomyocytes with mutations in ion-channel genes can accurately predict changes in cardiac electrical properties and reveal drug sensitivities. Dr. Mummery will describe similar studies that use vascular endothelial cells from hPSC and discuss the appropriate bioassays to measure disease phenotypes.
Subjects:	Cardiovascular Diseases--drug therapy Cardiovascular Diseases--pathology Induced Pluripotent Stem Cells Myocytes, Cardiac
Publication Types:	Lecture Webcast

NLM Classification:	WG 142
NLM ID:	101700299
CIT Live ID:	21595
Permanent link:	https://videocast.nih.gov/watch=21595

Related Videos...